Suppliers and packagers for generic pharmaceutical drug: nelfinavir mesylate

nelfinavir mesylate

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	020779	NDA	AGOURON	63010-010-30	300 TABLET, FILM COATED in 1 BOTTLE (63010-010-30)	1997-03-14
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	021503	NDA	AGOURON	63010-027-70	120 TABLET, FILM COATED in 1 BOTTLE (63010-027-70)	2003-04-30

Suppliers for Nelfinavir Mesylate: API and Finished-Dose Sources, Supply Chain Risks, and IP/Regulatory Constraints

Last updated: May 26, 2026

Nelfinavir mesylate is an established HIV protease inhibitor with a long history of use, but current sourcing is shaped by (1) limited active commercial supply in some markets, (2) reliance on a narrow set of API and packaging/labeling networks, and (3) regulatory constraints tied to historical approvals and market withdrawals. There is no current, reliable single “supplier list” that is stable across jurisdictions without tying to a specific geography, dosage form (tablet vs. powder/suspension configurations), and approved label.

What companies supply nelfinavir mesylate (API) and who supplies finished tablets?

Featured snippet answer: Nelfinavir mesylate supply today is dominated by a small group of global generic/antiretroviral manufacturers that maintain historic dossiers, plus contract manufacturing and repackaging networks. Finished-dose product availability often depends on local distributors and tender-driven sourcing rather than broad commercial brand supply.

API supply: typical sourcing model

API for older HIV small molecules is frequently sourced through:

• API producers selling to generic formulators through long-term contracts
• Brokered procurement of API lots tied to specific CoAs and impurity profiles
• Contract manufacturing organizations (CMOs) supporting crystallization, drying, and milling steps that affect impurity control

Finished dose supply: typical sourcing model

For nelfinavir mesylate tablets and any alternative oral presentations:

• Generic manufacturers procure API and perform formulation, compression, coating, and packaging
• Local wholesalers/distributors handle regulatory distribution and product substitution
• Labeling and blistering are frequently outsourced to regional packaging plants

Practical implication for procurement

Even if the API is available globally, the market risk is often in finished product continuity: tablets may be produced in campaigns, and supply interruptions can be driven by packaging line capacity, regulatory batch release timing, and lot qualification timelines.

Which manufacturers are known for nelfinavir-containing products?

Featured snippet answer: Known suppliers for nelfinavir products in the market have historically included originators and multiple generic manufacturers, but current availability can be discontinuous by region.

Historical originator context

• Nelfinavir was originally developed and marketed by a large branded HIV portfolio holder (widely cited originator era), but branded supply has shifted over time with changing antiretroviral formularies and market dynamics.
• In current procurement practice, branded product supply is often less relevant than generic or tender-specific sourcing.

Generic supply reality check

For older antiretrovirals, the supplier set changes more often than for newer drugs because:

• Regulatory maintenance costs are high
• Demand is lower and more fragmented
• Some manufacturers focus on higher-margin and higher-demand ARVs

What is the FDA regulatory status of nelfinavir mesylate that affects sourcing?

Featured snippet answer: Sourcing for a listed drug is constrained by whether the product remains actively marketed under an FDA-approved application and whether the Orange Book lists patents that determine generic entry and maintenance.

Orange Book dependency

To determine which companies can lawfully market specific nelfinavir mesylate products, buyers typically rely on:

• FDA “Approved Drug Products with Therapeutic Equivalence Evaluations” (Orange Book) listings
• Current Applicant of Record and NDA/ANDA status
• Patent and exclusivity listings tied to the listed drug

Market availability dependency

Even when an ANDA exists, a supplier may not ship consistently due to:

• Batch release and stability program requirements
• Drug substance supply continuity
• Manufacturing site inspections and remediation cycles

How do Paragraph IV challenges and patent status affect supply timing?

Featured snippet answer: Patent and exclusivity status can delay generic or authorized supply entry, but for nelfinavir’s era the dominant procurement driver is often whether products are still manufactured and maintained, not whether new generics can enter.

Patent estate effects

If patents were listed and enforced historically, generic supply could be delayed until:

• Patent expiration
• Settlement agreements
• Licensing arrangements
• Post-expiration re-approvals or manufacturing site transfers

Procurement impact

For buyers, the effect is seen as:

• Historic lockout for certain labeled strengths
• A limited number of suppliers that invested in ongoing commercial production
• Occasional re-emergence of additional generics after manufacturing restarts

What dosage forms and strengths drive supplier availability?

Featured snippet answer: Sourcing constraints are strongest for less common strengths or presentations, where packaging lines and demand are limited.

Tablets vs. oral powder considerations

• Tablets: formulation and coating requirements matter, and supply is often tied to a small number of compression/film-coating trains.
• Alternative oral presentations: may require different wet-granulation, taste-masking, or excipient systems, which reduces the number of plants willing to run them.

Strength-specific supply risk

For procurement planning, the key operational risk is not only API availability but also:

• Lot-to-lot impurity drift control
• Dissolution profile consistency
• Packaging component supply (blister lidding, bottle sealing, desiccants)

Which contract manufacturers and distributors participate in the supply chain?

Featured snippet answer: Many suppliers rely on CMOs for niche steps: drying, particle size adjustment, film coating, and packaging. Distributors vary by region and tender structure.

CMO roles in nelfinavir mesylate production

Typical CMO tasks include:

• Scale-up batch manufacture and validation runs
• Tablet press and coating operations
• Packaging line execution and labeling
• Stability sample management and ongoing CoA generation

Distributor roles

Distributors often handle:

• Regulatory importation
• Distribution in limited formularies
• Lot tracking and pharmacovigilance reporting support

What supply chain risks are most relevant for nelfinavir mesylate sourcing?

Featured snippet answer: The main risks are discontinuous commercial production, regulatory lot release delays, and API lot qualification issues tied to impurity profiles.

API qualification risks

• Different polymorph or crystal habit can change impurities and dissolution behavior
• Particle size and milling can shift assay and impurity ranges
• CoA credibility depends on controlled impurity specifications and analytical methods alignment

Finished-dose release risks

• Stability shelf-life and stability commitment changes can affect release
• Packaging component substitutions can create revalidation triggers
• Batch release timing can misalign with clinical/tender schedules

How does nelfinavir mesylate compare with other HIV protease inhibitors for supplier breadth?

Featured snippet answer: Nelfinavir tends to have narrower supplier breadth than more widely used, newer, or higher-demand protease inhibitors, which increases procurement volatility.

Competitive landscape effect

• Drugs with broader demand usually have more active manufacturing capacity and more sustained regulatory maintenance
• Older agents with declining utilization often see reduced supplier counts and longer lead times

Key Takeaways

• Nelfinavir mesylate supply is shaped by discontinuous manufacturing and region-specific distribution rather than broad, constantly available global supply.
• Procurement risk is concentrated in finished-dose continuity, packaging availability, and regulatory batch release timelines.
• Supplier identification in practice must be tied to FDA-listed status and local market tender/distribution channels to ensure continuity and label compliance.
• API availability alone does not remove supply risk, since finished-dose formulation and lot qualification are typically the bottlenecks.

FAQs

1. How do I verify the manufacturer of a specific nelfinavir mesylate lot?
   Check the product label and lot-specific CoA, cross-reference with the NDA/ANDA applicant for the listed drug, and validate lot release date and storage conditions.

2. Are nelfinavir mesylate tablets interchangeable across manufacturers?
   They may be therapeutically equivalent if the FDA equivalence standard supports it, but excipient and dissolution profile differences can matter clinically for sensitive patients.

3. What leads to nelfinavir mesylate backorders during tenders?
   Finished-dose manufacturing campaigns, packaging line constraints, and delays in regulatory batch release.

4. What regulatory documents are most important for import of nelfinavir mesylate?
   NDA/ANDA reference product details, lot CoA, shipping/storage documentation, and pharmacovigilance and batch traceability documentation.

5. How should API substitution be handled for nelfinavir mesylate production?
   Require impurity profile comparability, dissolution matching, and validation of critical quality attributes before using the substituted API source in commercial batches.

References

1. U.S. Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). (Accessed via FDA Orange Book database).
2. FDA. Drug Approval Packages: NDA/ANDA application records and labeling information (accessed via FDA Drugs@FDA).
3. U.S. FDA. Drugs@FDA database.